Zacks Investment Research lowered shares of Enanta Pharmaceuticals (NASDAQ:ENTA) from a buy rating to a hold rating in a research report released on Tuesday morning.
According to Zacks, “Enanta Pharmaceuticals, Inc. is a biotechnology company. It engages in the research and development of molecule drugs for the treatment of infectious diseases such as hepatitis C virus, respiratory tract infections, intravenous and oral treatments. Enanta Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts. “
Several other research analysts have also weighed in on the company. JMP Securities reaffirmed a buy rating and issued a $120.00 target price on shares of Enanta Pharmaceuticals in a research report on Tuesday, July 31st. BidaskClub lowered Enanta Pharmaceuticals from a buy rating to a hold rating in a research report on Tuesday, July 24th. UBS Group lowered Enanta Pharmaceuticals from an outperform rating to a market perform rating in a research report on Wednesday, August 8th. Finally, Oppenheimer set a $100.00 target price on Enanta Pharmaceuticals and gave the stock a hold rating in a research report on Tuesday, August 14th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, two have given a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of Hold and an average target price of $104.00.
Enanta Pharmaceuticals stock traded up $0.78 during mid-day trading on Tuesday, hitting $79.62. The company’s stock had a trading volume of 1,252 shares, compared to its average volume of 336,738. The company has a market cap of $1.57 billion, a P/E ratio of 86.64 and a beta of 0.80. Enanta Pharmaceuticals has a 52-week low of $44.52 and a 52-week high of $127.77.
Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings data on Tuesday, August 7th. The biotechnology company reported $0.97 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.98 by ($0.01). Enanta Pharmaceuticals had a return on equity of 25.84% and a net margin of 37.63%. The business had revenue of $57.26 million during the quarter, compared to analysts’ expectations of $56.59 million. Research analysts forecast that Enanta Pharmaceuticals will post 3.56 earnings per share for the current year.
In other Enanta Pharmaceuticals news, insider Tim Ocain sold 25,000 shares of the company’s stock in a transaction dated Monday, October 1st. The stock was sold at an average price of $83.64, for a total value of $2,091,000.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Nathalie Adda sold 4,155 shares of the company’s stock in a transaction dated Thursday, September 20th. The stock was sold at an average price of $95.32, for a total value of $396,054.60. Following the completion of the transaction, the vice president now directly owns 4,155 shares in the company, valued at $396,054.60. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 33,310 shares of company stock worth $2,870,644. Insiders own 10.56% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of the company. United Services Automobile Association increased its holdings in shares of Enanta Pharmaceuticals by 1.7% during the 2nd quarter. United Services Automobile Association now owns 37,289 shares of the biotechnology company’s stock valued at $4,322,000 after acquiring an additional 635 shares during the last quarter. State Board of Administration of Florida Retirement System increased its holdings in shares of Enanta Pharmaceuticals by 7.8% during the 2nd quarter. State Board of Administration of Florida Retirement System now owns 8,849 shares of the biotechnology company’s stock valued at $1,026,000 after acquiring an additional 640 shares during the last quarter. Rhumbline Advisers increased its holdings in shares of Enanta Pharmaceuticals by 1.9% during the 2nd quarter. Rhumbline Advisers now owns 37,550 shares of the biotechnology company’s stock valued at $4,352,000 after acquiring an additional 691 shares during the last quarter. Legal & General Group Plc increased its holdings in shares of Enanta Pharmaceuticals by 3.1% during the 1st quarter. Legal & General Group Plc now owns 27,064 shares of the biotechnology company’s stock valued at $2,175,000 after acquiring an additional 805 shares during the last quarter. Finally, Cubist Systematic Strategies LLC increased its holdings in shares of Enanta Pharmaceuticals by 27.0% during the 1st quarter. Cubist Systematic Strategies LLC now owns 5,850 shares of the biotechnology company’s stock valued at $473,000 after acquiring an additional 1,243 shares during the last quarter. 77.68% of the stock is currently owned by institutional investors and hedge funds.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company's research and development focuses on disease targets: hepatitis B virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and respiratory syncytial virus.
Featured Article: Marijuana Stocks Investing Considerations
Get a free copy of the Zacks research report on Enanta Pharmaceuticals (ENTA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.